Long non-coding RNA GAS5 contributes to the progression of nonalcoholic fatty liver disease by targeting the microRNA-29a-3p/NOTCH2 axis

References

• Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15:45.
   PubMed Web of Science ®Google Scholar
• Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49:197–211.
   PubMed Web of Science ®Google Scholar
• Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med (Lond). 2018;18:245–250.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism. 2016;65:1109–1123.
   PubMed Web of Science ®Google Scholar
• Ter Horst KW, Serlie MJ. Fructose consumption, lipogenesis, and non-alcoholic fatty liver disease. Nutrients. 2017;9. DOI:10.3390/nu9090981
   PubMed Web of Science ®Google Scholar
• Bedossa P. Pathology of non-alcoholic fatty liver disease. Liver Int. 2017;37(Suppl 1):85–89.
   PubMedGoogle Scholar
• Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77:3965–3981.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446–454.
   PubMed Web of Science ®Google Scholar
• Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;172:393–407.
   PubMed Web of Science ®Google Scholar
• Sun C, Liu X, Yi Z, et al. Genome-wide analysis of long noncoding RNA expression profiles in patients with non-alcoholic fatty liver disease. IUBMB Life. 2015;67:847–852.
   PubMed Web of Science ®Google Scholar
• Liu J, Tang T, Wang GD, et al. LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARgamma axis in non-alcoholic fatty liver disease. Biosci Rep. 2019;39(2):BSR20181722.
   Web of Science ®Google Scholar
• Wang X. Down-regulation of lncRNA-NEAT1 alleviated the non-alcoholic fatty liver disease via mTOR/S6K1 signaling pathway. J Cell Biochem. 2018;119:1567–1574.
   PubMed Web of Science ®Google Scholar
• Sun Y, Song Y, Liu C, et al. LncRNA NEAT1-MicroRNA-140 axis exacerbates nonalcoholic fatty liver through interrupting AMPK/SREBP-1 signaling. Biochem Biophys Res Commun. 2019;516:584–590.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen X, Gao J, et al. Long noncoding RNA FLRL2 alleviated nonalcoholic fatty liver disease through Arntl-Sirt1 pathway. FASEB J. 2019;33:11411–11419.
   PubMed Web of Science ®Google Scholar
• Guo J, Zhou Y, Cheng Y, et al. Metformin-induced changes of the coding transcriptome and non-coding RNAs in the livers of non-alcoholic fatty liver disease mice. Cell Physiol Biochem. 2018;45:1487–1505.
   PubMedGoogle Scholar
• Wu H, Zhong Z, Wang A, et al. LncRNA FTX represses the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via regulating the M1/M2 polarization of Kupffer cells. Cancer Cell Int. 2020;20:266.
   PubMed Web of Science ®Google Scholar
• Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141:1202–1207.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Huang SX, Zhang F, et al. MicroRNAs: a novel potential biomarker for diagnosis and therapy in patients with non-small cell lung cancer. Cell Prolif. 2017;50:e12394.
   PubMed Web of Science ®Google Scholar
• Fernandez-Tussy P, Fernandez-Ramos D, Lopitz-Otsoa F, et al. miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease. Mol Metab. 2019;29:40–54.
   PubMed Web of Science ®Google Scholar
• Jampoka K, Muangpaisarn P, Khongnomnan K, et al. Serum miR-29a and miR-122 as potential biomarkers for non-alcoholic fatty liver disease (NAFLD). Microrna. 2018;7:215–222.
   PubMedGoogle Scholar
• Sun C, Huang F, Liu X, et al. miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR. Int J Mol Med. 2015;35:847–853.
   PubMed Web of Science ®Google Scholar
• Argentou N, Germanidis G, Hytiroglou P, et al. TGF-beta signaling is activated in patients with chronic HBV infection and repressed by SMAD7 overexpression after successful antiviral treatment. Inflamm Res. 2016;65:355–365.
   PubMed Web of Science ®Google Scholar
• Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med. 2010;207:1589–1597.
   PubMed Web of Science ®Google Scholar
• Chung AC, Dong Y, Yang W, et al. Smad7 suppresses renal fibrosis via altering expression of TGF-beta/Smad3-regulated microRNAs. Mol Ther. 2013;21:388–398.
   PubMed Web of Science ®Google Scholar
• Santhekadur PK, Kumar DP, Sanyal AJ. Preclinical models of non-alcoholic fatty liver disease. J Hepatol. 2018;68:230–237.
   PubMed Web of Science ®Google Scholar
• Liu S, Xie X, Lei H, et al. Identification of key circRNAs/lncRNAs/miRNAs/mRNAs and pathways in preeclampsia using bioinformatics analysis. Med Sci Monit. 2019;25:1679–1693.
   PubMed Web of Science ®Google Scholar
• Li B, Zhu L, Li L, et al. lncRNA OXCT1-AS1 promotes metastasis in non-small-cell lung cancer by stabilizing LEF1, In Vitro and In Vivo. Biomed Res Int. 2021;2021:4959381.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592–1609.
   PubMed Web of Science ®Google Scholar
• Sattar N, Forrest E, Preiss D. Non-alcoholic fatty liver disease. Bmj. 2014;349:g4596.
   PubMed Web of Science ®Google Scholar
• Chen X, Tan XR, Li SJ, et al. LncRNA NEAT1 promotes hepatic lipid accumulation via regulating miR-146a-5p/ROCK1 in nonalcoholic fatty liver disease. Life Sci. 2019;235:116829.
   PubMed Web of Science ®Google Scholar
• Chen X, Xu Y, Zhao D, et al. LncRNA-AK012226 is involved in fat accumulation in db/db mice fatty liver and non-alcoholic fatty liver disease cell model. Front Pharmacol. 2018;9:888.
   PubMed Web of Science ®Google Scholar
• Shen X, Guo H, Xu J, et al. Inhibition of lncRNA HULC improves hepatic fibrosis and hepatocyte apoptosis by inhibiting the MAPK signaling pathway in rats with nonalcoholic fatty liver disease. J Cell Physiol. 2019;234:18169–18179.
   PubMed Web of Science ®Google Scholar
• Wang B, Li X, Hu W, et al. Silencing of lncRNA SNHG20 delays the progression of nonalcoholic fatty liver disease to hepatocellular carcinoma via regulating liver Kupffer cells polarization. IUBMB Life. 2019;71:1952–1961.
   PubMed Web of Science ®Google Scholar
• Zhang B, Li H, Li D, et al. Long noncoding RNA Mirt2 upregulates USP10 expression to suppress hepatic steatosis by sponging miR-34a-5p. Gene. 2019;700:139–148.
   PubMed Web of Science ®Google Scholar
• Ma TT, Huang C, Ni Y, et al. ATP citrate lyase and LncRNA NONMMUT010685 play crucial role in nonalcoholic fatty liver disease based on analysis of microarray data. Cell Physiol Biochem. 2018;51:871–885.
   PubMedGoogle Scholar
• Jin SS, Lin XF, Zheng JZ, et al. lncRNA NEAT1 regulates fibrosis and inflammatory response induced by nonalcoholic fatty liver by regulating miR-506/GLI3. Eur Cytokine Netw. 2019;30:98–106.
   PubMed Web of Science ®Google Scholar
• Liu XL, Cao HX, Wang BC, et al. miR-192-5p regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1. World J Gastroenterol. 2017;23:8140–8151.
   PubMed Web of Science ®Google Scholar
• Long JK, Dai W, Zheng YW, et al. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. Mol Med. 2019;25:26.
   PubMed Web of Science ®Google Scholar
• Dai LL, Li SD, Ma YC, et al. MicroRNA-30b regulates insulin sensitivity by targeting SERCA2b in non-alcoholic fatty liver disease. Liver Int. 2019;39:1504–1513.
   PubMed Web of Science ®Google Scholar
• Hanin G, Yayon N, Tzur Y, et al. miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression. Gut. 2018;67:1124–1134.
   PubMed Web of Science ®Google Scholar
• Fang QH, Shen QL, Li JJ, et al. Inhibition of microRNA-124a attenuates non-alcoholic fatty liver disease through upregulation of adipose triglyceride lipase and the effect of liraglutide intervention. Hepatol Res. 2019;49:743–757.
   PubMed Web of Science ®Google Scholar
• Csak T, Bala S, Lippai D, et al. microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis. Liver Int. 2015;35:532–541.
   PubMed Web of Science ®Google Scholar
• Xu M, Zheng XM, Jiang F, et al. MicroRNA-190b regulates lipid metabolism and insulin sensitivity by targeting IGF-1 and ADAMTS9 in non-alcoholic fatty liver disease. J Cell Biochem. 2018;119:5864–5874.
   PubMed Web of Science ®Google Scholar
• Lei L, Zhou C, Yang X, et al. Down-regulation of microRNA-375 regulates adipokines and inhibits inflammatory cytokines by targeting AdipoR2 in non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol. 2018;45:819–831.
   PubMed Web of Science ®Google Scholar
• Wu H, Ng R, Chen X, et al. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut. 2016;65:1850–1860.
   PubMed Web of Science ®Google Scholar
• Huang P, Huang FZ, Liu HZ, et al. LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6. Metabolism. 2019;94:1–8.
   PubMed Web of Science ®Google Scholar
• Wang XM, Wang XY, Huang YM, et al. Role and mechanisms of action of microRNA21 as regards the regulation of the WNT/betacatenin signaling pathway in the pathogenesis of nonalcoholic fatty liver disease. Int J Mol Med. 2019;44:2201–2212.
   PubMedGoogle Scholar
• Takeuchi-Yorimoto A, Yamaura Y, Kanki M, et al. MicroRNA-21 is associated with fibrosis in a rat model of nonalcoholic steatohepatitis and serves as a plasma biomarker for fibrotic liver disease. Toxicol Lett. 2016;258:159–167.
   PubMed Web of Science ®Google Scholar
• He H, Dai J, Feng J, et al. FBXO31 modulates activation of hepatic stellate cells and liver fibrogenesis by promoting ubiquitination of Smad7. J Cell Biochem. 2019. doi:10.1002/jcb.29528.
   Web of Science ®Google Scholar
• Zhu L, Wang L, Wang X, et al. Hepatic deletion of Smad7 in mouse leads to spontaneous liver dysfunction and aggravates alcoholic liver injury. PLoS One. 2011;6:e17415.
   PubMed Web of Science ®Google Scholar
• Feng T, Dzieran J, Gu X, et al. Smad7 regulates compensatory hepatocyte proliferation in damaged mouse liver and positively relates to better clinical outcome in human hepatocellular carcinoma. Clin Sci (Lond). 2015;128:761–774.
   PubMed Web of Science ®Google Scholar
• Zhu J, Zhang Z, Zhang Y, et al. MicroRNA-212 activates hepatic stellate cells and promotes liver fibrosis via targeting SMAD7. Biochem Biophys Res Commun. 2018;496:176–183.
   PubMed Web of Science ®Google Scholar
• Seyhan H, Hamzavi J, Wiercinska E, et al. Liver fibrogenesis due to cholestasis is associated with increased Smad7 expression and Smad3 signaling. J Cell Mol Med. 2006;10:922–932.
   PubMed Web of Science ®Google Scholar
• Ikejima K, Okumura K, Lang T, et al. The role of leptin in progression of non-alcoholic fatty liver disease. Hepatol Res. 2005;33:151–154.
   PubMed Web of Science ®Google Scholar
• Yang L, Roh YS, Song J, et al. Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. Hepatology. 2014;59:483–495.
   PubMed Web of Science ®Google Scholar